Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
Completed · Phase 1 · Has a placebo group
Conditions studied: LQT2 Syndrome
In brief
The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.
Key facts
- Study ID
- NCT02365506
- Run by
- Gilead Sciences
- People needed
- 13
- Starts
- 2015-07-20
- Expected to finish
- 2016-06-13
- Last updated by the study team
- 2020-12-30
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Rochester Medical Center/Strong Memorial Hospital — Rochester, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.